ASCO: Bristol Myers CMO brushes off LAG-3 concern in lung cancer after Opdualag's adjuvant melanoma flop
Despite its success in advanced melanoma, Bristol Myers Squibb’s fixed-dose PD-1/LAG-3 combo, Opdualag, failed to move the needle in resected skin cancer.
